ClinicalTrials.gg
RecruitingNCT06699433Updated Dec 19, 2024

Artificial Intelligence-driven Virtual Standardized Pediatric Patients Trial

An interventional study of Virtual standardized patients (VSPs) and Case teaching manuals in Pneumococcal Pneumonia, Rotavirus Enteritis With Hypovolemic Shock and Hand-foot-and-mouth Disease, sponsored by Southern Medical University, China. Recruiting at 3 sites in China. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by Southern Medical University, China · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
459
Allocation
Randomized
Sex
All
01

Study summary

Background: China's healthcare system for children faces significant challenges, particularly due to the limited pediatric service capacity of primary healthcare institutions. A shortage of effective and accessible training tools for primary care doctors further hinders progress in addressing this gap. Technological advancements, especially in artificial intelligence, offer a potential solution to improve pediatric care. Artificial intelligence-driven virtual standardized patients (VSPs), leveraging internet and virtual simulation technologies, simulate clinical cases with specific disease characteristics, providing an innovative, efficient, and flexible training method. VSPs are increasingly utilized in medical education, clinical reasoning, and licensure exams. This study focuses on using VSPs to improve the management of common pediatric conditions, which are major health concerns for children and impose significant psychological and financial burdens on families.

Methods: This study will involve a three-arm randomized controlled trial to evaluate the effectiveness of a virtual pediatric standardized patient platform in enhancing primary care doctors' management of common pediatric diseases. At least 459 participants, including general practitioners, internal medicine practitioners, surgeons, and pediatricians from more than 10 provinces across China, will be randomly assigned to one of three groups: the virtual patient platform group, the case teaching manual group, or the case teaching video group. Five virtual patient cases covering pneumococcal pneumonia, rotavirus enteritis with hypovolemic shock, hand-foot-and-mouth disease, acute appendicitis, and respiratory failure will be developed, along with corresponding case teaching materials. After a two-week learning period, participants' disease management abilities will be assessed using clinical vignettes. The primary outcome is adherence to best clinical practice guidelines, categorized into full adherence, partial adherence, and nonadherence.

Discussion: This study aims to leverage artificial intelligence for capacity enhancement, targeting the shortcomings of primary care pediatrics and using VSP to help enhance primary care pediatrics capacity. It is a randomized controlled trial involving over 300 primary healthcare institutions across more than 10 provinces in China, ensuring broad and representative participation from both developed and underdeveloped regions.

02

Conditions studied

  • Pneumococcal Pneumonia
  • Rotavirus Enteritis With Hypovolemic Shock
  • Hand-foot-and-mouth Disease
  • Acute Appendicitis
  • Respiratory Failure (Pediatric Patients)
03

In context

Pneumonia, Pneumococcal

44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.

This study's planned enrollment of 459 is above the median of 388 across 37 interventional studies indexed under Pneumonia, Pneumococcal.

Browse Pneumonia, Pneumococcal studies →

Lead sponsor

Southern Medical University, China is the lead sponsor of 32 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  1. Inclusion and Exclusion Criteria for Research Institutions

    Inclusion Criteria:

    • Primary and secondary hospitals
    • Community health centers (stations) and clinics, as well as township health centers and village health clinics

    Exclusion Criteria:

    • Specialized medical institutions (such as specialized hospitals and dental clinics)
    • Public health prevention and treatment institutions (such as tuberculosis prevention centers)
    • Ethnic medicine institutions (such as Mongolian and Tibetan hospitals)
    • Hospitals above the secondary level
    • Hospitals that have not yet been graded (due to their short establishment time and potentially unstable operations)
  2. Inclusion and exclusion criteria for research subjects

Inclusion Criteria:

  • Practicing (assistant) doctors and rural doctors working in medical institutions that meet the above conditions
  • With a scope of practice only including general practice, internal medicine, surgery, and pediatrics

Exclusion Criteria:

-None

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
459 participants (estimated)

Study arms

  • Experimental
    Virtual standardized patients (VSPs) training

    Virtual standardized patients (VSPs), utilizing internet and virtual simulation technology, emulate patients with specific disease characteristics and clinical manifestations. With advantages in safety, flexibility, convenience, and efficiency, VSPs are used in medical education, clinical reasoning training, and licensure examinations. Doctors will interact with VSPs to conduct clinical simulations and training, including consultations, physical examinations, auxiliary examinations, and treatment decision-making, to enhance their capabilities for managing common pediatric diseases

    Behavioral: Virtual standardized patients (VSPs)

  • Experimental
    Case teaching manuals

    Doctors will use case teaching manuals to enhance their capabilities for managing common pediatric diseases

    Behavioral: Case teaching manuals

  • Experimental
    Case teaching videos

    Doctors will use case teaching videos to enhance their capabilities for managing common pediatric diseases

    Behavioral: Case teaching videos

Interventions

  • BehavioralVirtual standardized patients (VSPs)

    Virtual standardized patients (VSPs), utilizing internet and virtual simulation technology, emulate patients with specific disease characteristics and clinical manifestations. With advantages in safety, flexibility, convenience, and efficiency, VSPs are used in medical education, clinical reasoning training, and licensure examinations. Doctors will interact with VSPs to conduct clinical simulations and training, including consultations, physical examinations, auxiliary examinations, and treatment decision-making, to enhance their capabilities for managing common pediatric diseases

  • BehavioralCase teaching manuals

    Doctors will use case teaching manuals to enhance their capabilities for managing common pediatric diseases

  • BehavioralCase teaching videos

    Doctors will use case teaching videos to enhance their capabilities for managing common pediatric diseases

06

What researchers measure

Primary outcomes

  1. Doctor adherence to best clinical practice guidelines

    Doctor adherence to best clinical practice guidelines, i.e., the extent to which doctors consistently make judgments and treatments based on best clinical practice guidelines and progression of the disease. Ordered categorical variable, consisting of three grades: full adherence, partial adherence, and nonadherence. It will be measured using clinical vignette method.

    Time frame: Through study completion, an average of 6 months

Secondary outcomes

  1. Dichotomous variable of doctor adherence to best clinical practice guidelines

    Dichotomous variable of doctor adherence to best clinical practice guidelines. Dichotomous variable, consisting of two categories: full adherence, partial adherence or no adherence. It will be measured using clinical vignette method.

    Time frame: Through study completion, an average of 6 months

  2. The degree of accuracy of a doctor's diagnosis according to best clinical practice guidelines

    The degree of accuracy of a doctor's diagnosis according to best clinical practice guidelines. Ordered categorical variable, consisting of three categories: fully correct, partially correct, incorrect. It will be measured using clinical vignette method.

    Time frame: Through study completion, an average of 6 months

  3. Doctor score of examination that is directly related to handling the disease

    Doctor score of examination that is directly related to handling the disease. It is a continuous variable. It will be measured using examination paper called Disease Handling Capacity Scale. The lowest score is 0, the highest score is 5, and higher scores mean a better outcome.

    Time frame: Through study completion, an average of 6 months

  4. Doctor score of examination that is related to expansion skills of handling the disease

    Doctor score of examination that is related to expansion skills of handling the disease. It is a continuous variable. It will be measured using examination paper called Expanded Disease Handling Capacity Scale. The lowest score is 0, the highest score is 5, and higher scores mean a better outcome.

    Time frame: Through study completion, an average of 6 months

  5. The level at which the doctor focuses on meeting the actual needs of the patient and gives due consideration to the patient's feelings

    The level at which the doctor focuses on meeting the actual needs of the patient and gives due consideration to the patient's feelings. It is a continuous variable. It will be measured using team-developed patient-centered situational question test paper method.

    Time frame: Through study completion, an average of 6 months

  6. Adoption of training by doctors

    Implementation outcome: Adoption of training by doctors. Dichotomous variable, consisting of two categories: adopted, not adopted. It will be measured using team-developed questionnaire (self-reported by doctors).

    Time frame: Through study completion, an average of 6 months

  7. Costs to researchers of developing and implementing three types of training

    Implementation outcome: Costs to researchers of developing and implementing three types of training. It is a continuous variable. It will be measured using project final account of expenditure.

    Time frame: Through study completion, an average of 6 months

  8. Doctor score of acceptability of three types of training

    Implementation outcome: Doctor score of acceptability of three types of training. It is a continuous variable. It will be measured using generic Theoretical Framework of Acceptability (TFA)-based questionnaire self-reported by doctors.

    Time frame: Through study completion, an average of 6 months

07

Study locations

3 of 3 sites recruiting
  • Yuntan Street Community Health Center
    Guiyang, Guizhou 550081, China
    Recruiting
  • Jinxi County People's Hospital
    Fuzhou, Jiangxi 344899, China
    Recruiting
  • Honghe County People's Hospital
    Honghe, Yunnan 654499, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All collected IPD, all IPD that underlie results in a publication, are to be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Starting 6 months after publication

Access criteria: All collected IPDs will be provided in a timely manner to anyone who has a valid reason for requesting data from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2024; primary completion for Dec 2024, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2024
First posted
Nov 21, 2024
StartEst.
Dec 2024
Primary completionEst.
Dec 2024
CompletionEst.
Jan 2025
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06699433
Lead sponsor
Southern Medical University, China
Responsible party
Dr. Huanyuan Luo (Professor, Southern Medical University, China) — Principal investigator
First posted
Nov 21, 2024
Start date
Dec 2024 (estimated)
Primary completion
Dec 2024 (estimated)
Completion
Jan 2025 (estimated)
Last update
Dec 19, 2024

Study contacts

Luo
Contact
huanyuanluo33@gmail.com
+86-19566890018
Yao Zhao, Doctor
principal investigator · National Clinical Research Center for Child Health and Disorders, Chongqing, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion